Yeast Infection Market based on Pathogen Type (Candida albicans, Candida glabrata, Candida rugosa, and Others), Infection Type (Vaginal Infection, Throat Infection, Skin Infection, Esophagus Infection, and Others), Treatment (Medications, Creams/Ointments, Probiotics, and Others), End Users (Clinics, Hospitals, Ambulatory centers, and Others) and Geography – Global Forecast up to 2027
Yeast Infection is a general type of fungal infection. Yeast infection causes on several parts of the human body, such as skin, oral cavity, and intestines. The most common yeast infection is a vaginal yeast infection, widely observed among women, and it is called candidal vaginitis or candidal vulvovaginitis (CVV). Moreover, the common fungus responsible for vaginal yeast infection is Candida Albicans. The Yeast Infection Market is expected to grow at the rate of 5.65% CAGR by 2027. Owing to several reasons such as unhygienic conditions, weak immunity, and a favorable environment for the growth of the related microbes, yeast infection can cause a key reason for market growth. Apart from infants, people who have diabetes, obesity, hypothyroidism, and inflammatory disorders are more vulnerable to catching yeast infection, elevating the demand for yeast infection treatment. The global yeast infection market is further driven by the constantly rising geriatric population and an increasing number of patients suffering from HIV. However, the difficulties during treatments and various treatment-associated side effects are limiting the growth of the market.
Yeast Infection Market based on Pathogen Type
As observed in the infection type, the vaginal infection segment has the maximum share in the market. This is due to the overgrowth of candida which causes yeast infections vagina. In addition, the vaginal infection type is expected in people due to the weak immune system, stress, and lack of sleep, eventually augmenting the segment growth.
The medication segment has a major share in the yeast infection market compared to treatments. Medication is considered the effective way to get rid of yeast infection and is considered the fastest treatment. Moreover, the medication also works in preventing yeast infection.
As in the market by end-users, the hospitals' segment held the major share in the market. The key share is attributed to the increasing number of patients suffering from yeast infection and the availability of better treatments in the hospitals.
In terms of geography, North America is expected to have a major contribution to market growth. An increase in yeast infection and the number of cases of vaginal infections is a major factor propelling the market in the region. Moreover, the increasing burden of the urology patient population and advanced healthcare infrastructure are also responsible factors.
The rising number of invasive candidiasis and vaginal candidiasis incidence and premature births worldwide have a high economic burden on the patient population, as a result, augments the global yeast infection market growth. Candidemia, the common form of invasive candidiasis, is the most typical bloodstream infection, resulting in long hospital stays. Moreover, this type of infection is considered a fatal infection, increasing the demand for yeast infection treatments.
The yeast infection market report provides a few notable companies such as Astellas Pharma Inc., Brundavan Laboratories Private Limited, Synmedic Laboratories Pvt Ltd, Merck & Co., Inc., Astra Zeneca Plc, Abbott Laboratories, Allergan Plc, Bayer AG, Corden Pharma GmbH, and Pfizer Inc.
Henceforth, yeast infection treatment has a prominent role as these types of infections have increased enormously due to the shifting lifestyles of the people. Moreover, the yeast infection market is witnessing the highest growth rate as candidiasis infections increase daily.
Yeast Infection Market based on Pathogen Type
- Candida albicans
- Candida glabrata
- Candida rugosa
- Others
- Vaginal Infection
- Throat Infection
- Skin Infection
- Esophagus Infection
- Others
- Medications
- Creams/Ointments
- Probiotics
- Others
- Clinics
- Hospitals
- Ambulatory centers
- Others
- North America
- Europe
- Asia Pacific
- Rest of the World
As observed in the infection type, the vaginal infection segment has the maximum share in the market. This is due to the overgrowth of candida which causes yeast infections vagina. In addition, the vaginal infection type is expected in people due to the weak immune system, stress, and lack of sleep, eventually augmenting the segment growth.
The medication segment has a major share in the yeast infection market compared to treatments. Medication is considered the effective way to get rid of yeast infection and is considered the fastest treatment. Moreover, the medication also works in preventing yeast infection.
As in the market by end-users, the hospitals' segment held the major share in the market. The key share is attributed to the increasing number of patients suffering from yeast infection and the availability of better treatments in the hospitals.
In terms of geography, North America is expected to have a major contribution to market growth. An increase in yeast infection and the number of cases of vaginal infections is a major factor propelling the market in the region. Moreover, the increasing burden of the urology patient population and advanced healthcare infrastructure are also responsible factors.
The rising number of invasive candidiasis and vaginal candidiasis incidence and premature births worldwide have a high economic burden on the patient population, as a result, augments the global yeast infection market growth. Candidemia, the common form of invasive candidiasis, is the most typical bloodstream infection, resulting in long hospital stays. Moreover, this type of infection is considered a fatal infection, increasing the demand for yeast infection treatments.
The yeast infection market report provides a few notable companies such as Astellas Pharma Inc., Brundavan Laboratories Private Limited, Synmedic Laboratories Pvt Ltd, Merck & Co., Inc., Astra Zeneca Plc, Abbott Laboratories, Allergan Plc, Bayer AG, Corden Pharma GmbH, and Pfizer Inc.
Henceforth, yeast infection treatment has a prominent role as these types of infections have increased enormously due to the shifting lifestyles of the people. Moreover, the yeast infection market is witnessing the highest growth rate as candidiasis infections increase daily.
- This report segments the yeast infection market exclusively and provides the nearest estimation of the overall market size and the sub-segments across key regions.
- This study assists shareholders in understanding the market and gives information on key market propellants, restraints, challenges, and opportunities.
- This research would also assist shareholders in identifying their competitors better and achieving more information to intensify their position in the business.
- The report also focuses on the competitive outlook, including product launches, acquisitions, mergers, and partnerships of the players.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. PATHOGEN TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Candida albicans
5.3. Candida glabrata
5.4. Candida rugosa
5.5. Others
6. INFECTION TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Vaginal Infection
6.3. Throat Infection
6.4. Skin Infection
6.5. Esophagus Infection
6.6. Others
7. TREATMENT: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Medications
7.3. Creams/Ointments
7.4. Probiotics
7.5. Others
8. END USERS: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. Clinics
8.3. Hospitals
8.4. Ambulatory centers
8.5. Others
9. GEOGRAPHY: MARKET SIZE & ANALYSIS
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. COMPETITIVE LANDSCAPE
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. VENDOR PROFILES
11.1. Astellas Pharma Inc.
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. Brundavan Laboratories Private Limited
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Synmedic Laboratories Pvt Ltd
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. Merck & Co., Inc.
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Astra Zeneca Plc
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Abbott Laboratories
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Allergan Plc
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Bayer AG
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Corden Pharma GmbH
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. Pfizer Inc.
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy
12. ANALYST OPINION
13. ANNEXURE
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. PATHOGEN TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Candida albicans
5.3. Candida glabrata
5.4. Candida rugosa
5.5. Others
6. INFECTION TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Vaginal Infection
6.3. Throat Infection
6.4. Skin Infection
6.5. Esophagus Infection
6.6. Others
7. TREATMENT: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Medications
7.3. Creams/Ointments
7.4. Probiotics
7.5. Others
8. END USERS: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. Clinics
8.3. Hospitals
8.4. Ambulatory centers
8.5. Others
9. GEOGRAPHY: MARKET SIZE & ANALYSIS
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. COMPETITIVE LANDSCAPE
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. VENDOR PROFILES
11.1. Astellas Pharma Inc.
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. Brundavan Laboratories Private Limited
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Synmedic Laboratories Pvt Ltd
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. Merck & Co., Inc.
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Astra Zeneca Plc
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Abbott Laboratories
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Allergan Plc
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Bayer AG
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Corden Pharma GmbH
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. Pfizer Inc.
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy
12. ANALYST OPINION
13. ANNEXURE
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA ALBICANS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA GLABRATA, BY TYPE, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA RUGOSA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL YEAST INFECTION MARKET VALUE FOR VAGINAL INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL YEAST INFECTION MARKET VALUE FOR THROAT INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL YEAST INFECTION MARKET VALUE FOR SKIN INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL YEAST INFECTION MARKET VALUE FOR ESOPHAGUS INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL YEAST INFECTION MARKET VALUE FOR MEDICATIONS, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL YEAST INFECTION MARKET VALUE FOR CREAMS/OINTMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL YEAST INFECTION MARKET VALUE FOR PROBIOTICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. GLOBAL YEAST INFECTION MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
TABLE 18. GLOBAL YEAST INFECTION MARKET VALUE FOR CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 19. GLOBAL YEAST INFECTION MARKET VALUE FOR HOSPITALS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 20. GLOBAL YEAST INFECTION MARKET VALUE FOR AMBULATORY CENTERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 21. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 22. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 24. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 25. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 26. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 27. U.S YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 28. U.S YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.S YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 30. U.S YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 31. CANADA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 32. CANADA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 33. CANADA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 34. CANADA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 35. EUROPE YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 36. EUROPE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 37. EUROPE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 38. EUROPE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 39. EUROPE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 40. GERMANY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 41. GERMANY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 42. GERMANY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 43. GERMANY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 44. U.K YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 45. U.K YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 46. U.K YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 47. U.K YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 48. FRANCE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 49. FRANCE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 50. FRANCE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 51. FRANCE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 52. ITALY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 53. ITALY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 54. ITALY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 55. ITALY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 56. SPAIN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 57. SPAIN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 58. SPAIN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 59. SPAIN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 60. ROE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 61. ROE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 62. ROE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 63. ROE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 64. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 65. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 66. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 67. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 68. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 69. CHINA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 70. CHINA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 71. CHINA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 72. CHINA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 73. INDIA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 74. INDIA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 75. INDIA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 76. INDIA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 77. JAPAN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 78. JAPAN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 79. JAPAN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 80. JAPAN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 81. REST OF APAC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 82. REST OF APAC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 83. REST OF APAC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 84. REST OF APAC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 85. REST OF WORLD YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 86. REST OF WORLD YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 87. REST OF WORLD YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 88. REST OF WORLD YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 89. ASTELLAS PHARMA INC.: FINANCIALS
TABLE 90. ASTELLAS PHARMA INC.: PRODUCTS & SERVICES
TABLE 91. ASTELLAS PHARMA INC.: RECENT DEVELOPMENTS
TABLE 92. BRUNDAVAN LABORATORIES PRIVATE LIMITED: FINANCIALS
TABLE 93. BRUNDAVAN LABORATORIES PRIVATE LIMITED: PRODUCTS & SERVICES
TABLE 94. BRUNDAVAN LABORATORIES PRIVATE LIMITED: RECENT DEVELOPMENTS
TABLE 95. SYNMEDIC LABORATORIES PVT LTD: FINANCIALS
TABLE 96. SYNMEDIC LABORATORIES PVT LTD: PRODUCTS & SERVICES
TABLE 97. SYNMEDIC LABORATORIES PVT LTD: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO., INC: FINANCIALS
TABLE 99. MERCK & CO., INC: PRODUCTS & SERVICES
TABLE 100. MERCK & CO., INC: RECENT DEVELOPMENTS
TABLE 101. ASTRA ZENECA PLC: FINANCIALS
TABLE 102. ASTRA ZENECA PLC: PRODUCTS & SERVICES
TABLE 103. ASTRA ZENECA PLC: RECENT DEVELOPMENTS
TABLE 104. ABBOTT LABORATORIES: FINANCIALS
TABLE 105. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 106. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 107. ALLERGAN PLC: FINANCIALS
TABLE 108. ALLERGAN PLC: PRODUCTS & SERVICES
TABLE 109. ALLERGAN PLC: RECENT DEVELOPMENTS
TABLE 110. BAYER AG: FINANCIALS
TABLE 111. BAYER AG: PRODUCTS & SERVICES
TABLE 112. BAYER AG: RECENT DEVELOPMENTS
TABLE 113. CORDEN PHARMA GMBH: FINANCIALS
TABLE 114. CORDEN PHARMA GMBH: PRODUCTS & SERVICES
TABLE 115. CORDEN PHARMA GMBH: RECENT DEVELOPMENTS
TABLE 116. PFIZER INC: FINANCIALS
TABLE 117. PFIZER INC: PRODUCTS & SERVICES
TABLE 118. PFIZER INC: RECENT DEVELOPMENTS
TABLE 1. GLOBAL YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA ALBICANS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA GLABRATA, BY TYPE, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA RUGOSA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL YEAST INFECTION MARKET VALUE FOR VAGINAL INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL YEAST INFECTION MARKET VALUE FOR THROAT INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL YEAST INFECTION MARKET VALUE FOR SKIN INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL YEAST INFECTION MARKET VALUE FOR ESOPHAGUS INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL YEAST INFECTION MARKET VALUE FOR MEDICATIONS, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL YEAST INFECTION MARKET VALUE FOR CREAMS/OINTMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL YEAST INFECTION MARKET VALUE FOR PROBIOTICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. GLOBAL YEAST INFECTION MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
TABLE 18. GLOBAL YEAST INFECTION MARKET VALUE FOR CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 19. GLOBAL YEAST INFECTION MARKET VALUE FOR HOSPITALS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 20. GLOBAL YEAST INFECTION MARKET VALUE FOR AMBULATORY CENTERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 21. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 22. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 24. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 25. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 26. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 27. U.S YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 28. U.S YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.S YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 30. U.S YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 31. CANADA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 32. CANADA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 33. CANADA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 34. CANADA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 35. EUROPE YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 36. EUROPE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 37. EUROPE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 38. EUROPE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 39. EUROPE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 40. GERMANY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 41. GERMANY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 42. GERMANY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 43. GERMANY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 44. U.K YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 45. U.K YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 46. U.K YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 47. U.K YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 48. FRANCE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 49. FRANCE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 50. FRANCE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 51. FRANCE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 52. ITALY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 53. ITALY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 54. ITALY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 55. ITALY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 56. SPAIN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 57. SPAIN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 58. SPAIN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 59. SPAIN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 60. ROE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 61. ROE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 62. ROE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 63. ROE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 64. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 65. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 66. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 67. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 68. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 69. CHINA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 70. CHINA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 71. CHINA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 72. CHINA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 73. INDIA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 74. INDIA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 75. INDIA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 76. INDIA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 77. JAPAN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 78. JAPAN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 79. JAPAN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 80. JAPAN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 81. REST OF APAC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 82. REST OF APAC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 83. REST OF APAC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 84. REST OF APAC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 85. REST OF WORLD YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
TABLE 86. REST OF WORLD YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
TABLE 87. REST OF WORLD YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 88. REST OF WORLD YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 89. ASTELLAS PHARMA INC.: FINANCIALS
TABLE 90. ASTELLAS PHARMA INC.: PRODUCTS & SERVICES
TABLE 91. ASTELLAS PHARMA INC.: RECENT DEVELOPMENTS
TABLE 92. BRUNDAVAN LABORATORIES PRIVATE LIMITED: FINANCIALS
TABLE 93. BRUNDAVAN LABORATORIES PRIVATE LIMITED: PRODUCTS & SERVICES
TABLE 94. BRUNDAVAN LABORATORIES PRIVATE LIMITED: RECENT DEVELOPMENTS
TABLE 95. SYNMEDIC LABORATORIES PVT LTD: FINANCIALS
TABLE 96. SYNMEDIC LABORATORIES PVT LTD: PRODUCTS & SERVICES
TABLE 97. SYNMEDIC LABORATORIES PVT LTD: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO., INC: FINANCIALS
TABLE 99. MERCK & CO., INC: PRODUCTS & SERVICES
TABLE 100. MERCK & CO., INC: RECENT DEVELOPMENTS
TABLE 101. ASTRA ZENECA PLC: FINANCIALS
TABLE 102. ASTRA ZENECA PLC: PRODUCTS & SERVICES
TABLE 103. ASTRA ZENECA PLC: RECENT DEVELOPMENTS
TABLE 104. ABBOTT LABORATORIES: FINANCIALS
TABLE 105. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 106. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 107. ALLERGAN PLC: FINANCIALS
TABLE 108. ALLERGAN PLC: PRODUCTS & SERVICES
TABLE 109. ALLERGAN PLC: RECENT DEVELOPMENTS
TABLE 110. BAYER AG: FINANCIALS
TABLE 111. BAYER AG: PRODUCTS & SERVICES
TABLE 112. BAYER AG: RECENT DEVELOPMENTS
TABLE 113. CORDEN PHARMA GMBH: FINANCIALS
TABLE 114. CORDEN PHARMA GMBH: PRODUCTS & SERVICES
TABLE 115. CORDEN PHARMA GMBH: RECENT DEVELOPMENTS
TABLE 116. PFIZER INC: FINANCIALS
TABLE 117. PFIZER INC: PRODUCTS & SERVICES
TABLE 118. PFIZER INC: RECENT DEVELOPMENTS
LIST OF FIGURES
CHART. 1. GLOBAL YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 2. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA ALBICANS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 3. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA GLABRATA, BY TYPE, 2021-2027 (USD BILLION)
CHART. 4. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA RUGOSA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 5. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 6. GLOBAL YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 7. GLOBAL YEAST INFECTION MARKET VALUE FOR VAGINAL INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 8. GLOBAL YEAST INFECTION MARKET VALUE FOR THROAT INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 9. GLOBAL YEAST INFECTION MARKET VALUE FOR SKIN INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 10. GLOBAL YEAST INFECTION MARKET VALUE FOR ESOPHAGUS INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 11. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 12. GLOBAL YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 13. GLOBAL YEAST INFECTION MARKET VALUE FOR MEDICATIONS, 2021-2027 (USD BILLION)
CHART. 14. GLOBAL YEAST INFECTION MARKET VALUE FOR CREAMS/OINTMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 15. GLOBAL YEAST INFECTION MARKET VALUE FOR PROBIOTICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 16. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 17. GLOBAL YEAST INFECTION MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
CHART. 18. GLOBAL YEAST INFECTION MARKET VALUE FOR CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 19. GLOBAL YEAST INFECTION MARKET VALUE FOR HOSPITALS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 20. GLOBAL YEAST INFECTION MARKET VALUE FOR AMBULATORY CENTERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 21. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 22. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 23. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 24. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 25. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 26. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 27. U.S YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 28. U.S YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 29. U.S YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 30. U.S YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 31. CANADA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 32. CANADA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 33. CANADA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 34. CANADA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 35. EUROPE YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 36. EUROPE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 37. EUROPE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 38. EUROPE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 39. EUROPE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 40. GERMANY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 41. GERMANY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 42. GERMANY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 43. GERMANY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 44. U.K YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 45. U.K YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 46. U.K YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 47. U.K YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 48. FRANCE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 49. FRANCE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 50. FRANCE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 51. FRANCE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 52. ITALY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 53. ITALY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 54. ITALY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 55. ITALY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 56. SPAIN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 57. SPAIN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 58. SPAIN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 59. SPAIN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 60. ROE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 61. ROE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 62. ROE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 63. ROE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 64. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 65. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 66. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 67. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 68. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 69. CHINA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 70. CHINA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 71. CHINA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 72. CHINA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 73. INDIA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 74. INDIA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 75. INDIA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 76. INDIA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 77. JAPAN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 78. JAPAN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 79. JAPAN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 80. JAPAN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 81. REST OF APAC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 82. REST OF APAC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 83. REST OF APAC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 84. REST OF APAC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 85. REST OF WORLD YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 86. REST OF WORLD YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 87. REST OF WORLD YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 88. REST OF WORLD YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 1. GLOBAL YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 2. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA ALBICANS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 3. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA GLABRATA, BY TYPE, 2021-2027 (USD BILLION)
CHART. 4. GLOBAL YEAST INFECTION MARKET VALUE FOR CANDIDA RUGOSA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 5. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 6. GLOBAL YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 7. GLOBAL YEAST INFECTION MARKET VALUE FOR VAGINAL INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 8. GLOBAL YEAST INFECTION MARKET VALUE FOR THROAT INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 9. GLOBAL YEAST INFECTION MARKET VALUE FOR SKIN INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 10. GLOBAL YEAST INFECTION MARKET VALUE FOR ESOPHAGUS INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 11. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 12. GLOBAL YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 13. GLOBAL YEAST INFECTION MARKET VALUE FOR MEDICATIONS, 2021-2027 (USD BILLION)
CHART. 14. GLOBAL YEAST INFECTION MARKET VALUE FOR CREAMS/OINTMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 15. GLOBAL YEAST INFECTION MARKET VALUE FOR PROBIOTICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 16. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 17. GLOBAL YEAST INFECTION MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
CHART. 18. GLOBAL YEAST INFECTION MARKET VALUE FOR CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 19. GLOBAL YEAST INFECTION MARKET VALUE FOR HOSPITALS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 20. GLOBAL YEAST INFECTION MARKET VALUE FOR AMBULATORY CENTERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 21. GLOBAL YEAST INFECTION MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 22. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 23. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 24. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 25. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 26. NORTH AMERICA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 27. U.S YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 28. U.S YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 29. U.S YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 30. U.S YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 31. CANADA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 32. CANADA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 33. CANADA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 34. CANADA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 35. EUROPE YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 36. EUROPE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 37. EUROPE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 38. EUROPE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 39. EUROPE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 40. GERMANY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 41. GERMANY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 42. GERMANY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 43. GERMANY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 44. U.K YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 45. U.K YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 46. U.K YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 47. U.K YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 48. FRANCE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 49. FRANCE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 50. FRANCE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 51. FRANCE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 52. ITALY YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 53. ITALY YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 54. ITALY YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 55. ITALY YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 56. SPAIN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 57. SPAIN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 58. SPAIN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 59. SPAIN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 60. ROE YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 61. ROE YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 62. ROE YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 63. ROE YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 64. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 65. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 66. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 67. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 68. ASIA PACIFIC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 69. CHINA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 70. CHINA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 71. CHINA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 72. CHINA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 73. INDIA YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 74. INDIA YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 75. INDIA YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 76. INDIA YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 77. JAPAN YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 78. JAPAN YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 79. JAPAN YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 80. JAPAN YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 81. REST OF APAC YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 82. REST OF APAC YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 83. REST OF APAC YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 84. REST OF APAC YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 85. REST OF WORLD YEAST INFECTION MARKET VALUE, BY PATHOGEN TYPE, 2021-2027 (USD BILLION)
CHART. 86. REST OF WORLD YEAST INFECTION MARKET VALUE, BY INFECTION TYPE, 2021-2027 (USD BILLION)
CHART. 87. REST OF WORLD YEAST INFECTION MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
CHART. 88. REST OF WORLD YEAST INFECTION MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
